DSNKY Daiichi Sankyo Company Ltd (PK)

By Kyle Morris

AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer.

The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan--has been recommended in the EU by the European Medicines Agency as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

November 14, 2022 02:37 ET (07:37 GMT)

Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 5 2024 まで 6 2024

Daiichi Sankyo (PK) (USOTC:DSNKY)
過去 株価チャート
から 6 2023 まで 6 2024